IP 1162
Latest Information Update: 16 Jan 2019
At a glance
- Originator Shire Pharmaceuticals Group
- Class Hormonal replacements
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Menopausal syndrome
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 21 Jun 2000 Discontinued-I for Menopausal syndrome in United Kingdom (PO)
- 22 Sep 1997 Phase-I clinical trials for Menopausal syndrome in United Kingdom (PO)